Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib
Adalgisa Condoluci(Ente Ospedaliero Cantonale), Luca Ceriani(St Thomas' Hospital), Francesco Passamonti(University of Milan), Lodovico Terzi di Bergamo(Institute of Oncology Research), Lisa Milan(Ente Ospedaliero Cantonale), Georg Stüssi(Institute of Oncology Research), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Marina Deodato(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), B. Gerber(University of Zurich), Michele Merli(University of Insubria), Gabriela Forestieri(Institute of Oncology Research), Gaby Fahrni(University of Lucerne), Clara Deambrogi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Roberta Mattarucchi(University of Insubria), Michael Gregor(University of Lucerne), Alessio Bruscaggin(Institute of Oncology Research), Valeria Spina(Ente Ospedaliero Cantonale), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568